MarketLens

What Drove Guardant Health's Q4 2025 Performance and 2026 Outlook

6 months ago

SHARE THIS ON:

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

What Drove Carvana's Q4 2025 Performance

6 months ago

What Drove Honeywell's Strong Q4 2025 Performance

6 months ago

What Drove Lululemon’s Strong Q3 Performance and Upbeat Q4 Outlook

6 months ago

What Drove TransMedics' Stellar Q4 2025 Performance

6 months ago

Guardant Health Sees Shield, MRD and Oncology Testing Growth Accelerate

Guardant Health highlighted accelerating growth across oncology testing, MRD, and Shield colorectal screening at the Canaccord Genuity Growth Conference, citing expanding adoption, new reimbursement, ...

Stock News•4 weeks ago

Wall Street's Insights Into Key Metrics Ahead of Guardant Health (GH) Q2 Earnings

Guardant Health (GH) faces Q2 earnings scrutiny beyond revenue and EPS, with key operational metrics likely to drive investor sentiment for the quarter ended June 2026.

Stock News•1 months ago

Quest Diagnostics Incorporated (DGX) Q2 2026 Earnings Call Transcript

Quest Diagnostics (DGX) reported Q2 2026 earnings, with revenue rising 4% year-over-year to $2.5 billion, driven by higher testing volumes and acquisitions.

DGX

Stock News•1 months ago

Kestra Medical Technologies Q4 Earnings Call Highlights

Kestra Medical Technologies Q4 revenue rose sharply, driven by new accounts and deeper customer penetration. Fiscal 2027 guidance calls for continued growth, supported by an expanded commercial team.

KMTS